European Commission Approves Novartis' Cosentyx for Polymyalgia Rheumatica

Novartis has received approval from the European Commission for its drug Cosentyx (secukinumab) to treat polymyalgia rheumatica (PMR), expanding its therapeutic indications. This approval enhances Novartis' immunology portfolio and offers a new treatment option for patients with this inflammatory condition. The decision reflects the company's strategy to broaden the clinical applications of Cosentyx.